Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Treatment Leqembi Iqlik
Related Stocks: BIIB
Read the full articleYou might also wanna read
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in t
Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi
Leqembi Iqlik can now be given at home throughout the entire course of treatment, setting it apart from Eli Lilly’s Kisunla, the only other
Biogen (BIIB) Stock Jumps on Analyst Upgrade Before Key Alzheimer’s Data Release
Truist upgrades Biogen (BIIB) stock to Buy with $235 target ahead of Alzheimer's drug data. Shares rise 1.3% premarket on positive analyst o
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing con
FDA approves at-home starter dose of Eisai-Biogen Alzheimer’s drug
(Refiles to add media packaging code, USA-HEALTH/ALZHEIMERS; no change to text or headline) July 13 (Reuters) - The U.S. FDA on Monday appro
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
Biogen leaders took to an investor call today to defend the phase 2 readout of the company’s anti-tau Alzheimer’s disease candidate, which d
Comments
Sign in to join the conversation.
No comments yet. Be the first.